BioHarvest Sciences (NASDAQ:BHST) Posts Quarterly Earnings Results, Misses Expectations By $0.04 EPS

BioHarvest Sciences (NASDAQ:BHST) issued its quarterly earnings results on Monday. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.04), FiscalAI reports. The firm had revenue of $8.84 million during the quarter, compared to analysts’ expectations of $9.45 million. BioHarvest Sciences had a negative net margin of 32.54% and a negative return on equity of 76.03%.

BioHarvest Sciences Stock Up 0.4%

NASDAQ:BHST traded up $0.01 during trading hours on Tuesday, reaching $2.11. The company’s stock had a trading volume of 63,789 shares, compared to its average volume of 36,372. The company has a market cap of $41.38 million, a price-to-earnings ratio of -3.57 and a beta of 0.98. BioHarvest Sciences has a one year low of $1.82 and a one year high of $12.80. The business’s 50-day moving average is $2.77 and its 200-day moving average is $3.82. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.96 and a quick ratio of 2.44.

Institutional Trading of BioHarvest Sciences

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd acquired a new position in shares of BioHarvest Sciences during the 4th quarter valued at about $173,000. Osaic Holdings Inc. lifted its holdings in BioHarvest Sciences by 5,510.4% in the 4th quarter. Osaic Holdings Inc. now owns 35,233 shares of the company’s stock worth $183,000 after purchasing an additional 34,605 shares during the last quarter. Evercore Wealth Management LLC bought a new stake in BioHarvest Sciences during the fourth quarter worth approximately $724,000. Alyeska Investment Group L.P. acquired a new position in BioHarvest Sciences during the fourth quarter valued at approximately $3,929,000. Finally, Quadrature Capital Ltd bought a new position in shares of BioHarvest Sciences in the fourth quarter valued at approximately $140,000.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded BioHarvest Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 18th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $10.00.

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.